ABSTRACT Psoriatic Spectrum Diseases (PSD) affect over 8 million individuals in the U.S. living with psoriasis (PsO) or psoriatic arthritis (PsA) and encompass heterogeneous phenotypes of disease, ranging from plaque, guttate, palmoplantar, inverse, pustular, and erythrodermic forms of psoriasis, to synovial, enthesial, and axial forms of PsA. Here, we assembled a world class multidisciplinary team of scientists in PSD cohort assembly, clinical phenotyping, biosample acquisition, pathology, statistics, and bioinformatics, for the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) PSD Disease Teams (DTs). The major scientific goals of the PSD DT are to understand the cellular and molecular composition of distinct PSD endotypes and how they link with phenotypes, to identify how key pathogenic or regulatory cells spatially interact with each other and with environmental cues (i.e., microbiome), and to define at a single-cell level how the transition to PsA unfolds in the setting of PsO. To accomplish the goals of the PSD AMP, we propose the creation of the ELLIPSS (ELucidating the Landscape of Immunoendotypes in Psoriatic Skin and Synovium) Disease Team (DT). The AIMS of the ELLIPSS Team are to 1) to enroll diverse PSD cohorts and perform clinical phenotyping, data capture, and tissue collection. 2) to implement an effective management plan for the ELLIPSS multidisciplinary team. 3) to optimize interface of ELLIPSS team with AMP-AIM network. Lastly, a robust Opportunities Fund (OF) management program is proposed under the direction and leadership of Dr. James T. Elder at University of Michigan. The ELLIPSS PSD DT will efficiently integrate with the AMP AIM Network, facilitate collection of PSD biosamples, and help provide an unprecedented view of cell types and states, along with spatial and tissue interactions (skin, joint, blood, microbiome) to deconstruct/reconstruct the psoriatic disease spectrum.